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SUMMARY

GLP-2 and EGF signaling in a mouse TPN model and in patients
deprived of enteral nutrition.

Enteral nutrient deprivation reduced endogenous epidermal
growth factor (EGF) and glucagon-like peptide-2 signaling in
mice and human beings. In a mouse model of total parenteral nutrition, both exogenous EGF and glucagon-like peptide-2 required EGF receptors to attenuate mucosal atrophy,
however, only EGF required phosphatidylinositol 3-kinase/
protein kinase B signaling for this beneﬁcial response.

METHODS: Adult C57BL/6J, IEC-Egfrknock out (KO) and
IEC-pik3r1KO mice receiving TPN or enteral nutrition were
treated with EGF or GLP-2 alone or in combination with
reciprocal receptor inhibitors, GLP-2(3-33) or geﬁtinib.
Jejunum was collected and mucosal atrophy and IEC responses
were assessed by histologic, gene, and protein expression
analyses. In patients undergoing planned looped ileostomies,
fed and unfed ileum was analyzed.

BACKGROUND & AIMS: Total parenteral nutrition (TPN), a
crucial treatment for patients who cannot receive enteral
nutrition, is associated with mucosal atrophy, barrier dysfunction, and infectious complications. Glucagon-like peptide-2
(GLP-2) and epidermal growth factor (EGF) improve intestinal
epithelial cell (IEC) responses and attenuate mucosal atrophy in
several TPN models. However, it remains unclear whether
these 2 factors use distinct or overlapping signaling pathways
to improve IEC responses. We investigated the interaction of

RESULTS: Enteral nutrient deprivation reduced endogenous
EGF and GLP-2 signaling in mice and human beings. In the mouse
TPN model, exogenous EGF or GLP-2 attenuated mucosal atrophy and restored IEC proliferation. The beneﬁcial effects of EGF
and GLP-2 were decreased upon Geﬁtinib treatment and in TPNtreated IEC-EgfrKO mice, showing epidermal growth factor–receptor dependency for these IEC responses. By contrast, in
TPN-treated IEC-pi3kr1KO mice, the beneﬁcial actions of EGF
were lost, although GLP-2 still attenuated mucosal atrophy.
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CONCLUSIONS: Upon enteral nutrient deprivation, exogenous
GLP-2 and EGF show strong interdependency for improving IEC
responses. Understanding the differential requirements for
phosphatidylinositol 3-kinase/phosphoAKT (Ser473) signaling
may help improve future therapies to prevent mucosal atrophy.
(Cell Mol Gastroenterol Hepatol 2017;3:447–468; http://
dx.doi.org/10.1016/j.jcmgh.2016.12.005)
Keywords: Total Parenteral Nutrition; EGF; GLP-2; EGFR; PI3K;
Mucosal Atrophy.
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lthough total parenteral nutrition (TPN) is vital
for the nutritional support of patients who cannot
tolerate enteral nutrition, TPN is associated with mucosal
atrophy and loss of intestinal integrity that can lead to
numerous clinical complications, including higher rates of
bacterial translocation and septicemia.1–4 A more detailed
understanding of the signaling pathways responsible for
TPN-related intestinal complications therefore is needed
to improve therapeutic options and clinical outcomes for
patients dependent on TPN. Teduglutide, a stable
analog of glucagon-like peptide 2 (GLP-2), is one new
therapeutic approach that is undergoing extensive
clinical trials for the treatment of patients with intestinal
failure.5,6 A recent report showed long-term teduglutide
treatment was effective in reducing parenteral support in
patients with short-bowel syndrome (SBS),6 however, the
mechanisms underlying the beneﬁcial actions of GLP-2
and its analogs in the gut are complex and still poorly
deﬁned.
GLP-2 (1-33) is a 33-amino acid peptide hormone
secreted by enteroendocrine L cells in the distal small bowel
and proximal colon but its biological actions are primarily in
the proximal small intestine.7 The main stimulus for GLP-2
secretion is the presence of enteral nutrients, such as fats
and carbohydrates. However, because GLP-2 receptors
(GLP2Rs) are expressed only in enteric neurons, enteroendocrine cells, and subepithelial myoﬁbroblasts, the majority of GLP-2 actions on the mucosal epithelium occur
indirectly through paracrine mediators. The trophic actions
of GLP-2 on crypt cell proliferation occur through complex
signaling events involving several paracrine factors,
including insulin-like growth factors (IGFs), epidermal
growth factor (EGF), and other erythroblastic leukemia viral
oncogene homolog (ErbB) ligands and keratinocyte growth
factors that are produced by nonepithelial cells that act in a
region-speciﬁc and context-dependent manner.8–10
Two of the most well-studied models of GLP-2 action are
mucosal growth in response to exogenous GLP-2 administration and endogenous GLP-2 signaling required for
adaptive mucosal responses after refeeding.8,9 Previous
studies using Igf1-deﬁcient mice and intestinal epithelial cell
(IEC)-speciﬁc IGF-1 receptor–deﬁcient mice have proposed
that IGF-1 produced by subepithelial myoﬁbroblasts is
required for the intestinotrophic actions of GLP-2, and both
exogenous GLP-2 and IGF-I can activate several growthrelated signaling pathways including b-catenin, protein
kinase B (AKT), and c-Myc.11–14 However, GLP-2 can still
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induce AKT activation in IGF-1–deﬁcient mice,11,14 suggesting that other growth factors contribute to the beneﬁcial
actions of GLP-2 in the intestine. For example, exogenous
GLP-2, but not IGF-I, was shown to selectively activate
ErbB ligand expression and this response was lost in
Glp2r-deﬁcient mice. Moreover, the induction of ErbB ligand
expression and enhanced crypt cell proliferation mediated
by exogenous GLP-2 was completely blocked by a pan-ErbB
inhibitor, showing that these GLP-2 responses were ErbB
dependent.15 Similarly, the same pan-ErbB inhibitor blocked
the adaptive growth response to refeeding in wild-type
(WT) mice. Refeeding failed to stimulate crypt cell proliferation in Glp2r-deﬁcient mice, however, exogenous EGF,
but not IGF-1, could restore this trophic response, which
was associated with increased AKT phosphorylation.16 By
contrast, the Holst laboratory reported that GLP-2
counteracted intestinal atrophy associated with high-dose
EGF-receptor (EGFR)-inhibitor treatment, suggesting an
alternative ﬁnding that GLP-2 may act independently of an
intact EGFR signaling pathway.17 Overall, these results
illustrate the complex nature of GLP-2’s actions in intestine
and show that several different paracrine signals are
involved in GLP-2–dependent signal transduction and
mucosal growth responses in vivo. However, the mechanisms regulating these different paracrine signals and the
potential for interdependency between their downstream
signaling transduction pathways have not been deﬁned.
The mouse TPN model is a valuable experimental
approach to study signal transduction pathways contributing to mucosal atrophy in the absence of acute inﬂammatory changes or small-bowel resection. The removal of
enteral nutrition is associated with decreased crypt proliferation, increased IEC apoptosis, a loss of epithelial barrier
function, and altered enteric microbiota, resulting in a mild
proinﬂammatory state and mucosal atrophy.4 We previously
showed that tumor necrosis factor (TNF)a/TNFa-receptor
1–mediated down-regulation of functional EGFR signaling in
IECs leads to a signiﬁcant decrease in IEC proliferation and
increased IEC apoptosis, and is a major contributor to TPNassociated mucosal atrophy. Importantly, exogenous EGF is
able to attenuate mucosal atrophy by maintaining crypt cell
proliferation, a beneﬁcial response that is correlated with
†

Deceased.

Abbreviations used in this paper: bp, base pair; EGF, epidermal growth
factor; EGFR, epidermal growth factor receptor; GLP-2, glucagon-like
peptide 2; GLP2R, glucagon-like peptide 2 receptor; GLP-2 (3-33),
glucagon-like peptide 2 antagonist; IEC, intestinal epithelial cell; IGF-1,
insulin-like growth factor 1; ISC, intestinal stem cell; IV, intravenous;
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short-bowel syndrome; TNF, tumor necrosis factor; TPN, total parenteral nutrition; TUNEL, terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling; WT, wild-type.
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restoration of EGFR signaling and partial recovery of AKT
phosphorylation.18–21
In several different animal TPN models, including the
mouse TPN model, exogenous GLP-2 also can improve IEC
responses and attenuate mucosal atrophy, further showing
that both EGF and GLP-2 are important trophic factors that
share many overlapping biological actions in this
model.22–28 In the present study, we examined the interdependency of EGF and GLP-2 and downstream signaling
pathways in the mouse TPN model and report several
ﬁndings. First, we showed that endogenous GLP-2 and EGF
signaling is diminished in the mouse TPN model. Second,
exogenous EGF and GLP-2 treatments attenuated TPNinduced mucosal atrophy. When the same growth factor
treatments were combined with reciprocal inhibitor
studies using GLP-2 (3-33) and geﬁtinib, respectively, we
found a strong interdependency of EGF and GLP-2
signaling pathways in preventing the TPN-associated
decrease in IEC proliferation and increase in IEC
apoptosis. By using intestinal cell–speciﬁc Egfr-deﬁcient
and intestinal cell–speciﬁc phosphatidylinositol 3-kinase
p85a (pi3kr1)-deﬁcient mice, we further showed that
both factors require functional EGFR signaling in IECs for
their beneﬁcial actions. However, the requirements for
functional phosphatidylinositol 3-kinase (PI3K)/phosphoAKT (Ser473) (pAKT) signaling in IECs are divergent.
Exogenous EGF is completely dependent on PI3K/pAKT
signaling within IECs, whereas GLP-2 is only partially
dependent on this pathway and appears to modulate IEC
proliferation via Wnt/b-catenin signaling. Finally, analysis
of paired human samples of distal small bowel from fed
and unfed individuals showed that nutrient deprivation
reduced EGF, EGFR, and proglucagon messenger RNA
(mRNA) levels and was associated with reduced proliferation and increased apoptotic marker expression. Overall,
these ﬁndings show important and unique interactions
between EGF and GLP-2 that may help guide future therapies to prevent mucosal atrophy, and potentially augment
the treatment of disorders such as SBS.

Materials and Methods
Mice
C57BL/6J (Jackson Laboratory, Bar Harbor, ME) were
used in this study. Villin-Cre, Egfrtm1Dwt (termed Egfrﬂox),
Ah-Cre, and Pik3r1tm1Lca (termed pik3r1ﬂox) mouse strains on
a C57BL/6J background have been described elsewhere.29–33
Villin-Cre and Egfrﬂox/ﬂox mice were interbred to generate
intestine-speciﬁc Egfr-knockout mice (Villin-Cre;Egfrﬂox/ﬂox;
termed IEC-Egfrknock out [KO]) and genotype control Egfrﬂox/ﬂox
mice. Recombination and loss of EGFR expression in isolated
crypts from adult IEC-EgfrKO mice was assessed at the
genomic DNA and mRNA level. DNA samples from isolated
colonic crypts were genotyped for Egfrﬂox (also called Egfrf),
recombined EgfrD, and Villin-Cre alleles by polymerase chain
reaction (PCR). Conditions were 35 cycles (30 s at 94 C, 1
min at 60 C, and 1 min at 72 C) with Taq DNA polymerase
(Qiagen, Valencia, CA). The Egfrf primers were lox3-forward:
5’-GGAGGAAAAGAAAGTCTGCC -3’ and lox3-reverse:
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5’-CCCATAGTTGGATAGGATGG-3’. The Vil-Cre allele primers
were CRE-forward: 5’-ACCTGAAGATGTTCGCGATTATCT-3’
and lox3-reverse: 5’-ACCGTCAGTACGTGAGATATCTT-3’.
A 348–base pair (bp) PCR product was generated from the
Egfrf allele and a 320-bp PCR product from the wild-type
allele (not shown). An approximately 350-bp PCR product
was generated from the Vil-Cre allele. Cre-recombined Egfr
allele was detected by PCR using 40 cycles (30 s at 94 C, 20 s
at 60 C, and 20 s at 72 C) with primers delta-3 5’-CTCAGCCAGATGATGTTGAC-3’ and Delta-4 5’-CCTCGTCTGTGGAAGAACTA-3’. A 129-bp PCR fragment was ampliﬁed from the
recombined Egfr allele. For analysis of Egfr mRNA expression, total RNA was extracted from isolated colonic crypts
using TRIzol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. One microgram of RNA was
used as a template for synthesis of complementary DNA using random primers (Gibco-BRL, Carlsbad, CA) and SuperScript III RT (Life Technologies, Grand Island, NY) in a total
reaction volume of 20 uL. The Cre-recombined EgfrD allele
has Egfr exon 3 deleted. Real-time PCR was performed using
2 sets of primers anchored within exon 3 using the ﬂanking
exons, exon 2 (exons 2–3) or exon 4 (exons 3–4). The complementary DNA was used as a template for PCR ampliﬁcation of exons 2–3 and exons 3–4, respectively. For exons 2–3,
35 cycles (30 s at 94 C, 1 min at 60 C, and 1 min at 72 C) with
primers exon 2 forward: 5’-ATGAAAACACCTATGCCTTAGCC3’, and exon 3 reverse: 5’-TAAGTTCCGCATGGGCAGTTC-3’.
The predicted wild-type band was 83 bp. For exons 3–4, 35
cycles (30 s at 98 C, 1 min at 60 C, and 1 min at 72 C) with
primers exon 3 forward: 5’-CCCATGCGGAACTTACAGGAA-3’
and exon 4 reverse: 5’- TTGGATCACATTTGGGGCAAC-3’. The
predicted wild-type band was 172 bp.
Ah-Cre and pik3r1ﬂox/ﬂox mice were interbred to generate
conditional Pik3r1-knockout mice (Ah-Cre;pik3r1ﬂox/ﬂox;
termed IEC-pik3r1KO mice). In IEC-pik3r1KO mice, Cre
recombinase was induced by intraperitoneal injection of 80
mg/kg of b-naphthoﬂavone (Sigma, St. Louis, MO) dissolved
in corn oil (8 mg/mL; Sigma) during the 6 days before TPN
administration. Upon Cre recombinase expression, a speciﬁc
deletion of active PI3K was observed within the small and
large intestinal epithelium owing to a loss of p85a, p55a,
and p50a subunits as previously described.31 All mice were
maintained under speciﬁc pathogen-free conditions in a
controlled temperature, humidity, and light environment.
All experimental procedures were conducted in accordance
with the University Committee on Use and Care of Animals
at the University of Michigan (no. 03986) and University of
Colorado (B102614 (01)1E).

Parenteral Nutrition Animal Model
Sex- and age-matched (10–12 weeks of age) mice
initially were fed ad libitum with standard mouse chow and
water, and allowed to acclimate for 1 week before surgery.
During the administration of intravenous (IV) solutions,
mice were housed in metabolic cages to prevent coprophagia. Catheterized mice initially received 5% dextrose
in 0.45 N saline, with 20 mEq of KCl/L at 4.8 mL/day as
described previously.19,21 After 24 hours, mice were
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randomized to enteral fed control or TPN groups. Enteral
controls received intravenous solution at 0.2 mL/h and
standard laboratory chow. TPN mice received IV TPN
solution at 4.8 mL/day. Nitrogen and energy delivery were
matched between groups (isonitrogenous/isocaloric). Mice
were killed 7 days after cannulation using CO2.
For exogenous growth factor studies, mice received
recombinant human EGF (50 mg/kg/day; Sigma-Aldrich,
St. Louis, MO) by oral gavage twice daily or human GLP2 (1-33) (termed GLP-2) (100 mg/kg/day; CA Peptide
Research, Napa, CA) subcutaneously by Alzet minipump

A

(Durect Corp, Cupertino, CA). In both cases, growth factor
administration was started after day 1 of TPN and
continued until mice were killed as outlined in
Figure 1.10,17,19,34
For EGFR kinase inhibitor studies, mice received geﬁtinib (2.5 mg/mL in 1% aqueous Tween 80, 200 mL; LC
Laboratories, Woburn, MA) by oral gavage twice daily,
starting 3 days before IV cannulation and continued until
mice were killed.19,21 In previous TPN studies, we have
shown that geﬁtinib does not alter crypt cell proliferation or
crypt depth in sham-treated control mice.19 Geﬁtinib is a

Catheterization

Day 0
TPN Treatment Groups:
1.
2.

Start
TPN

Day 7
TPN solution without chow

Control + saline: saline + std. chow
TPN: TPN solution w/o chow
+ oral saline
Saline infusion
+ std. chow

B

Catheterization
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1.
2.

Day 0

Start TPN +
GLP-2 or EGF

TPN + EGF: TPN + EGF,
oral, BID, 50ug/kg/day
TPN + GLP-2: TPN + GLP-2,
mini pump, s/c, 100ug/kg/day
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C

Harvest

Day -3

Day 1

Gefitinib
oral, BID
50ug/kg/day

GLP-2
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Figure
1. Schematic
outline of mouse TPN
model
and
different
growth
factor
and
receptor inhibition experiments performed in
this study. (A) Standard
TPN mouse model. (B)
TPN and exogenous GLP2 and EGF treatment regimens. (C) TPN and growth
factor treatment regimens
combined with reciprocal
receptor inhibition. Upper
panel: TPN þ GLP-2 þ
EGFR kinase inhibitor
geﬁtinib. Lower panel:
TPN þ EGF þ GLP-2
antagonist, GLP-2 (3-33).
bid, twice daily; s/c,
subcutaneously;
std,
standard.
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speciﬁc inhibitor for EGFR and does not cross-react with
other ErbB receptors.35 For GLP-2–inhibitor studies, mice
received GLP-2–receptor antagonist GLP-2 (3-33) (100 mg/
kg/day; CA Peptide Research) subcutaneously by Alzet
minipump, starting 3 days before IV cannulation and
continued until mice were killed.36,37 In some experiments,
treatment combinations of EGF with GLP-2 (3-33) and GLP2 with geﬁtinib were used as outlined in Figure 1. Control
mice received a vehicle solution.

Real-Time PCR
Freshly isolated mouse jejunal crypts or mucosal
scrapings were placed immediately into TRIzol (Invitrogen,
Carlsbad, CA) and RNA extraction was processed as
described previously.18,19 Quantitative reverse-transcription
PCR was performed with SYBR Green dye (ThermoFisher
Scientiﬁc, Carlsbad, CA) using mouse primers as previously
described18,19 or using human primers listed in Table 1.
Expression levels were determined with triplicate assays
per sample and normalized to the expression of 18S
ribosomal RNA.

Western Blotting
IECs were isolated from the jejunum, protein extracts
were prepared, and then immunoblotting was performed as
described previously.19,38 Protein levels were expressed as
a ratio to glyceraldehyde-3-phosphate dehydrogenase protein levels except for analysis of Egfr recombination in IECs
of IEC-EgfrKO mice, in which b-actin was used as a loading
control. In some experiments, IECs were separated further
into nuclear and cytosolic fractions for immunoblotting as
described previously.39,40 For cytoplasmic extracts, protein
levels were expressed as a ratio to glyceraldehyde3-phosphate dehydrogenase protein levels, whereas for
nuclear extracts, protein levels were expressed as a ratio
to histone H3 protein levels. Western blotting was performed using primary antibodies outlined in Table 2.
Secondary antibodies were the corresponding horseradishperoxidase–conjugated goat anti-mouse antibody or goat
anti-rabbit antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA).

Immunohistochemistry and Immunoﬂuorescence
Zinc-formalin ﬁxed (10%) and parafﬁn-embedded tissue
sections and 4% paraformaldehyde-ﬁxed frozen tissue
sections of jejunum were stained using standard immunostaining procedures as described previously.19,21 Immunostaining was performed using primary antibodies outlined
in Table 2.

Intestinal Morphology Assessment
Small intestinal length from the pyloric sphincter to the
ileocecal sphincter was measured. Villus height and crypt
depth were measured in at least 10 well-oriented,
full-length crypt-villus units per specimen and averaged as
described previously.21
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Table 1.Primer List
Gene

Sequence

h-GCG-F (proglucagon)

GCAGACCCACTCAGTGATCC

h-GCG-R (proglucagon)

GAATGTGCCCTGTGAATGGC

h-GLP2R-F

GAATGTGCCCTGTGAATGGC

h-GLP2R-R

CTGAGCTCTCTTCACTCCACC

h-EGF-F

CTTGGGAGCCTGAGCAGAAA

h-EGF-R

GCTGCTGCAGTTTCCTTTCC

h-EGFR-F

CCTGGTCTGGAAGTACGCAG

h-EGFR-R

GCGATGGACGGGATCTTAGG

h-PCNA-F

CAGAGCTCTTCCCTTACGCA

h-PCNA-R

GTCCTTGAGTGCCTCCAACA

h-BCL2-F

GGTGAACTGGGGGAGGATTG

h-BCL2-R

GCCCAGACTCACATCACCAA

h-BCLXL-F (BCL21)

GAACTGGGGGAGGATTGTGG

h-BCLXL-R (BCL21)

CCGTACAGTTCCACAAAGGC

h-ACTB-F

GTCATTCCAAATATGAGATGCGT

h-ACTB-R

GCTATCACCTCCCCTGTGTG

m-Egf-F

TTCTCACAAGGAAAGAGCATCTC

m-Egf-R

GTCCTGTCCCGTTAAGGAAAAC

m-Egfr-F

GCATCATGGGAGAGAACAACA

m-Egfr-R

TCAGGAACCATTACTCCATAGGT

m-Glp2r-F

GGAGACAGTTCAGAAGTGGGC

m-Glp2r-R

GCCAGCACACGTACTTATCAAA

m-Igf1-F

CTGGACCAGAGACCCTTTGC

m-Igf1-R

GGACGGGGACTTCTGAGTCTT

m-Igf1r-F

GTGGGGGCTCGTGTTTCTC

m-Igf1r-R

GATCACCGTGCAGTTTTCCA

m-Actb-F

ATGGAGCCGGACAGAAAAGC

m-Actb-R

CTTGCCACTCAGGGAAGGA

18S rRNA-F

GTAACCCGTTGAACCCCATT

18S rRNA-R

CCATCCAATCGGTAGTAGCG

GCG, proglucagon; Igf1r, insulin-like growth factor 1 receptor; rRNA, ribosomal RNA.

IEC Proliferation and Apoptosis Measurements
For IEC proliferation, immunoﬂuorescent staining of
proliferating cell nuclear antigen (PCNA) was performed as
described previously.19 The total number of proliferating
cells per crypt was deﬁned as the mean of proliferating cells
in 10 crypts for each mouse. The results are expressed as a
Proliferation Index (the number of PCNA-positive cells per
crypt) and then converted to percentage of controls (control
values set at 100%). PCNA protein and mRNA levels in cell
extracts also were expressed relative to controls. Terminal
deoxynucleotidyl
transferase–mediated
deoxyuridine
triphosphate nick-end labeling (TUNEL) assay was performed following the manufacturer’s instructions (R&D
Systems, Minneapolis, MN). Immunoﬂuorescent staining for
cleaved caspase-3 was performed to assess IEC apoptosis as
described previously.19 The results are expressed as an
Apoptotic Index (the percentage of active caspase3–positive cells/villi using a mean of 10 villi per mouse) as
described previously.19
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Table 2.Antibody List
Antibody

Source

Application/
dilution

Phospho-AKT (S473)

Cell Signaling,
Danvers, MA

WB, 1:1000

Total AKT

Cell Signaling

WB, 1:1000

Phospho-b-catenin
(S552)

Cell Signaling

WB, 1:500

Phospho-b-catenin
(S33/37/T41)

Cell Signaling

WB, 1:500

Total b-catenin

Cell Signaling

WB, 1:1000

Cleaved caspase 3

Cell Signaling

IF, 1:50

Chromogranin A

Santa Cruz
Biotechnology

IF, 1:200

Cyclin D1

Cell Signaling

WB, 1:500

EGFR

Santa Cruz
Biotechnology

WB, 1:1000

GAPDH

Santa Cruz
Biotechnology

WB, 1:500

or perforation were excluded because each of these pathologies may intrinsically change IEC proliferation/apoptosis
status independently of nutrient delivery.41,42 All specimens
were taken fresh to the Pathology Department from the
Operating Room. Portions of intestine not needed for pathologic evaluation were placed into RPMI 1640 with glutamine
(Invitrogen, Carlsbad, CA) for immediate transport to the
laboratory on ice. An approximately 1-cm2 segment of tissue
underwent mucosal scraping and was snap-frozen in TRIzol
for mRNA analysis. If available, a second segment was placed
into optimum cutting temperature embedding compound
(PELCO International, Redding, CA), and snap-frozen for
subsequent immunoﬂuorescence staining.

Data Analysis

Phospho-GSK3b (S9)

Cell Signaling

WB, 1:500

Total GSK3 b

Cell Signaling

WB, 1:1000

Histone H3

Santa Cruz
Biotechnology

WB, 1:500

PCNA

Rabbit, Cell Signaling

WB, 1:2000

PCNA

Rabbit monoclonal
antibody, Cell
Signaling

IF, 1:2000

c-Myc

Cell Signaling

WB, 1:500

b-actin

Cell Signaling

WB, 1:500

Data were expressed as means ± SEM. Statistical analysis
used unpaired t tests for comparison of 2 means, and a 1way analysis of variance for comparison of multiple
groups (with a Tukey post hoc analysis to assess statistical
differences between groups). For analysis of human fed and
unfed intestinal samples, a paired t test with a nonparametric Wilcoxon matched-pairs signed rank test was used.
All statistical analysis was performed using Prism 6 software (GraphPad Software, Inc, San Diego, CA). Statistical
signiﬁcance was deﬁned at a P value of less than .05.

Results

GAPDH,
glyceraldehyde-3-phosphate
dehydrogenase;
IF, immunoﬂuorescence; WB, Western blot.

Plasma GLP-2 Measurements
Plasma GLP-2 was measured by radioimmunoassay with
an N-terminal–speciﬁc antiserum that measures only GLP-2
with an intact N-terminus as previously described.23 Blood
was collected into chilled tubes containing EDTA (1 mg/
mL), Diprotin A/L (0.1 mmol/L; MP Biomedicals,
Aurora, OH), and aprotinin (0.01 mmol/L; Calbiochem, La
Jolla, CA) to avoid GLP-2 degradation.

Human Intestinal Tissue Analysis
All experiments were performed in accordance with the
University of Michigan Hospital Institutional Review Board,
Institutional Review Board (HUM00024263). All patients
with planned loop ileostomy takedowns were considered.
This allowed evaluation of fed and unfed small bowel from
the same patient via paired analysis, with the proximal
ileostomy being exposed to enteral nutrition and the distal
segment isolated from enteric ﬂow. To avoid the inherent
differences between jejunum and ileum, all samples were
from loop ileostomies of the distal ileum. Patients were fed
orally and did not receive parenteral nutrition. Stoma duration was at least 6 weeks for all patients. Patients with
Crohn’s disease, necrotizing enterocolitis, and acute ischemia

Plasma GLP-2 and Mucosal GLP2R Levels Are
Reduced in TPN-Treated WT Mice
GLP2R and EGFR/ErbB pathways are essential components of the signaling network involved in intestinal growth
responses and for adaptive mucosal responses to fasting
and refeeding.15,16 In the mouse TPN model, we previously
showed that EGFR protein levels in IECs and mucosal Egf
mRNA levels are reduced markedly in TPN-treated WT mice
compared with sham controls (Figure 2A and B).19 To
determine whether components of endogenous GLP-2
signaling also were altered in the TPN model, we examined plasma GLP-2 levels and intestinal GLP-2 receptor
(GLP2R) expression in TPN-treated WT and sham control
mice. In TPN-treated WT mice, there was a signiﬁcant 2-fold
decrease in plasma GLP-2 levels compared with sham controls (sham: 32.1 ± 9.5 pmol/L vs TPN: 15.7 ± 9.4 pmol/L; P
< .0001) (Figure 2C). Likewise, mucosal Glp2r mRNA levels
were decreased signiﬁcantly in TPN-treated WT mice
compared with sham controls (Figure 2D). Thus, similar to
decreased functional EGFR signaling detected in the TPN
model, these results suggest that endogenous mucosal
GLP-2 signaling also is reduced in TPN-treated mice.

Exogenous EGF Restores Plasma GLP-2 Levels
and Mucosal GLP2R Expression Whereas
Exogenous GLP-2 Restores Mucosal EGF mRNA
Levels in TPN-Treated WT Mice
Recent studies have shown that treatment with either
exogenous EGF or GLP-2 can attenuate mucosal atrophy in
TPN-treated WT mice.19,25 To determine whether these
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growth factor treatments altered endogenous EGF and
GLP-2 signaling in the TPN model, we examined the same
signaling parameters in TPN-treated WT mice given exogenous EGF, GLP-2, or vehicle alone (Figure 1). In agreement
with our previous studies,19 exogenous EGF restored functional EGFR protein levels in IECs of TPN-treated mice
(Figure 2A). However, this same EGF treatment failed to
restore mucosal Egf mRNA expression in TPN-treated mice
(Figure 2B). Based on these earlier-described observations,
we tested whether exogenous EGF treatment also could
affect endogenous GLP-2 signaling in TPN-treated WT mice.
Surprisingly, exogenous EGF treatment restored plasma
GLP-2 (EGF, 34.7 ± 6.6 pmol/L) levels and mucosal Glp2r
mRNA expression in TPN-treated WT mice to sham levels
(Figure 2C and D). These results suggest that restoration of
endogenous GLP-2 signaling may contribute to the actions
of exogenous EGF treatment in reducing mucosal atrophy in
TPN-treated WT mice.
We next examined the effects of exogenous GLP-2
treatment on the same signaling parameters in the TPN
model. As expected, exogenous GLP-2 administration
dramatically increased the plasma GLP-2 level more than
200-fold over the sham group (657 ± 172.8 pmol/L)
(Figure 2C). However, exogenous GLP-2 treatment failed to
alter mucosal Glp2r mRNA levels, which remained at the
reduced levels found in TPN-treated WT mice (Figure 2D).
Although exogenous GLP-2 did not improve EGFR protein
levels in IECs of TPN-treated mice (Figure 2A), the downregulation of mucosal Egf mRNA levels in TPN-treated
mice was completely prevented by exogenous GLP-2 treatment (Figure 2B). Thus, exogenous EGF prevents the loss of
plasma GLP-2 levels and mucosal Glp2r mRNA expression
whereas exogenous GLP-2 prevents the loss of mucosal Egf
mRNA levels in TPN-treated mice. Taken together, these
results suggest EGF and GLP-2 signaling pathways interact
with each other upon enteral nutrient deprivation.

Exogenous GLP-2 and EGF Treatments
Attenuate TPN-Induced Mucosal Atrophy
To further investigate the interdependence of GLP-2 and
EGF signaling within the TPN model, we ﬁrst conﬁrmed that
both exogenous growth factor treatments attenuate mucosal
atrophy in TPN-treated WT mice.19,25 H&E analyses of
jejunal tissue sections showed that TPN-treated WT mice
given vehicle alone had mucosal atrophy with a signiﬁcant
reduction in crypt depth and villus height compared with
their sham controls (Figure 2E). By contrast, TPN-treated
WT mice given either exogenous GLP-2 or EGF showed
protection against mucosal atrophy with signiﬁcant
improvement in both crypt depth and villus height
(Figures 2E and 3A and B).
Reduced crypt cell proliferation and increased IEC
apoptosis are important features of mucosal atrophy
observed in TPN-treated WT mice.18,19,21 To determine
whether exogenous GLP-2 or EGF can maintain crypt cell
proliferation in the TPN model, we compared PCNA
expression in TPN-treated WT mice administered exogenous GLP-2, EGF, or vehicle alone. In agreement with

Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 3

previous ﬁndings, TPN-treated WT mice given vehicle alone
showed a marked reduction in PCNA staining whereas both
exogenous GLP-2 and EGF treatments restored crypt cell
proliferation to sham control levels (Figure 3C). To test
whether the beneﬁcial effects of exogenous GLP-2 and EGF
treatments in the TPN model extended to attenuation of IEC
apoptosis, we examined TUNELþ staining in IECs. As expected, TPN-treated WT mice given vehicle alone had a
marked increase in TUNELþ staining compared with sham
controls whereas TPN-treated WT mice administered
exogenous GLP-2 or EGF showed a dramatic reduction in
TUNELþ staining with apoptotic indexes similar to sham
controls (Figure 3D). These results conﬁrm that both
exogenous GLP-2 and EGF treatments have signiﬁcant protective effects against TPN-induced mucosal atrophy that
include improvements in crypt depth and villus height,
restoration of crypt cell proliferation, and a reduction in IEC
apoptosis.

Blockade Studies Using EGFR Inhibitor Geﬁtinib
and GLP-2 Antagonist GLP-2 (3-33) Establish a
Strong Interdependence of GLP-2 and EGF
Signaling Pathways in Reducing Mucosal
Atrophy in the TPN Model
To further elucidate the interconnectivity of exogenous
EGF and GLP-2 signaling in attenuating TPN-induced
mucosal atrophy, we performed reciprocal inhibitor
studies using the EGFR kinase inhibitor geﬁtinib and the
GLP-2 antagonist GLP-2 (3-33). Previous studies have
reported that GLP-2 (3-33) can act either as a partial agonist
or antagonist for intestinal growth,34,43 however, the GLP-2
(3-33) dosing regimen used in the current TPN study elicited a weak antagonistic effect on crypt cell proliferation
and crypt depth in sham-treated control mice (Figure 4). In
WT mice receiving TPN and exogenous GLP-2, geﬁtinib was
given 3 days before administration of TPN and then
continued until mice were killed. Conversely, in WT mice
receiving TPN and exogenous EGF, GLP-2 (3-33) was given 3
days before administration of TPN and then continued until
mice were killed (Figure 1). In both experiments, the
opposing inhibitors completely blocked the respective
beneﬁcial responses of exogenous GLP-2 and EGF on
mucosal atrophy with crypt depth, villus height, and crypt
cell proliferation remaining at TPN levels (Figure 3A–D). In
addition, both inhibitor treatments signiﬁcantly increased
IEC apoptosis above TPN levels (Figure 3E). The results of
these inhibitor studies establish an important interdependent relationship between EGF and GLP-2 signaling pathways in their ability to attenuate mucosal atrophy in the
TPN model.

Exogenous GLP-2 and EGF Activation of pAkt
and Wnt/b-Catenin Signaling in IECs of
TPN-Treated Mice Involve Mutually Dependent
Signal Transduction Pathways
In IECs, pAKT and Wnt/b-catenin signaling pathways
play critical roles in regulating crypt cell proliferation and
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IEC survival. Notably, both exogenous GLP-2 and EGF
have been shown to activate pAKT (S473) and
Wnt/b-catenin (S552) signaling in several intestinal
adaptation and stress models.12,44–47 To assess changes in
the phosphorylation status and total protein levels of
AKT, b-catenin, glycogen synthase kinas 3 beta (GSK3b),
and the Wnt target genes cyclin D1 and c-Myc, Western
blot was performed from cytoplasmic and nuclear IEC
extracts prepared from WT mice receiving TPN. In TPNtreated WT mice, protein levels of pAKT (S473),
phospho-GSK3 beta (pGSK3b) (S9), and total b-catenin
were decreased signiﬁcantly whereas protein levels of
phospho-beta-catenin (p-b-catenin) (S33/37/T41) were
increased dramatically in the cytoplasm (Figure 5A).
Importantly, p-b-catenin (S552) protein levels in IEC nuclear extracts and the number of p-b-catenin
(S552)þ–stained nuclei in crypts were reduced
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signiﬁcantly (Figure 5B and C). These results are consistent with increased GSK3b activity and increased phosphorylation of b-catenin (S33/37/T41), leading to
increased proteasomal degradation of b-catenin. The
subsequent decrease in nuclear accumulation of
p-b-catenin (S552) and loss of Wnt transcriptional activity
is supported further by the marked reduction in cyclin D1
and c-Myc protein levels in nuclear extracts
(Figure 5B–D). Together, these results clearly show that
TPN administration signiﬁcantly reduces pAKT and Wnt/
b-catenin signaling within IECs; the dramatic decrease in
these 2 signaling pathways is consistent with the loss of
crypt cell proliferation and increased IEC apoptosis
observed in the TPN-treated WT mice.
By contrast, TPN-treated WT mice given exogenous GLP2 showed partial restoration of pAKT (S473) and a partial
reduction in p-b-catenin (S33/37/T41) protein levels,
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Figure 4. GLP-2 (3-33) administered to control mice
caused a slight reduction in intestinal growth. Shamtreated control mice received vehicle (phosphate-buffered
saline) or GLP-2–receptor antagonist GLP-2 (3-33) (100 mg/
kg/day) subcutaneously by Alzet minipump, starting 3 days
before IV cannulation and continued for another 7 days until
mice were killed. (A) Immunoﬂuorescent staining of PCNAþ
cells in the jejunum. (B) Quantiﬁcation of PCNAþ cells per
crypt. (C) Quantiﬁcation of small intestinal crypt depth (n ¼ 5
per group). Scale bars: 50 um. *P < .05. DAPI, 40 ,6-diamidino2-phenylindole.

whereas cytoplasmic pGSK3b (S9) and nuclear p-b-catenin
(S552) protein levels were completely restored to sham
control levels. Consistent with increased pAKT and Wnt/
b-catenin signaling and the restoration of cell proliferation
in the TPN-treated WT mice given GLP-2, exogenous GLP-2
completely restored cyclin D1 and partially restored c-Myc
nuclear protein levels in IECs. Similar increases in pAKT and
Wnt/b-catenin signaling were observed with TPN-treated
WT mice receiving exogenous EGF. Interestingly, exogenous EGF did not restore pGSK3 protein levels in IECs of
TPN-treated mice, suggesting that regulation of GSK3b may
be regulated differentially by these 2 growth factors in the
TPN model (Figure 5).
Mechanistically, the earlier described results show that
exogenous GLP-2 and EGF both attenuate mucosal atrophy
in the TPN model, in part by increasing pAKT and Wnt/
b-catenin signaling in IECs. To further show that EGF and
GLP-2 use the pAKT and Wnt/b-catenin signaling pathways in an interdependent manner, we again used reciprocal inhibitor studies using the EGFR kinase inhibitor
geﬁtinib and the GLP-2 antagonist GLP-2 (3-33) as
described earlier. Strikingly, blockade of either EGFR or
GLP2R prevented the beneﬁcial effects of the respective
growth factors on maintaining pAKT, p-b-catenin (S552),
cyclin D1, and c-Myc protein levels in the TPN-treated
mice (Figure 5). These results clearly show that GLP-2
and EGF both use common downstream signaling

Although GLP2R expression is highest in the jejunum,48
the lack of GLP2R expression within enterocytes and especially in the intestinal stem/crypt progenitor cells indicates
that exogenous GLP-2 mediates its effects on IEC responses
via indirect paracrine mechanisms.8–10,49 To investigate the
contribution of EGFR signaling within IECs for the beneﬁcial
actions of exogenous GLP-2 in the TPN model, we generated
IEC-speciﬁc Egfr-deﬁcient mice (termed IEC-EgfrKO mice).
Consistent with other reports,50 these IEC-EgfrKO mice were
healthy and had no overt intestinal phenotype with normal
crypt-villus architecture and crypt cell proliferation under
normal physiological conditions (Figure 6). Because TPN
administration in WT mice completely down-regulates
EGFR protein levels in IECs,19,21 only a direct comparison
of IEC responses to exogenous GLP-2 treatment in
TPN-treated IEC-EgfrKO and Egfrﬂ/ﬂ genotype control mice
was performed.
In TPN-treated genotype control mice, GLP-2 administration continued to prevent mucosal atrophy, but this
protective effect was reduced signiﬁcantly in TPN-treated
IEC-EgfrKO mice and was associated with decreased crypt
depth, villus height, and crypt cell proliferation, and a
marked increase in IEC apoptosis (Figure 7A–C). Importantly, the protective effect of GLP-2 on p-AKT and Wnt/
b-catenin signaling observed in the TPN-treated genotype
control mice was diminished signiﬁcantly in IEC-EgfrKO
mice receiving TPN (Figure 7D–G). Despite GLP-2 not
restoring EGFR protein levels in IECs of TPN-treated WT
mice (Figure 2), the results from TPN-treated IEC-EgfrKO
mice show that IEC-speciﬁc EGFR signaling plays a critical
role in how exogenous GLP-2 attenuates TPN-associated
mucosal atrophy. In the absence of intestinal EGFRs, the
loss of PI3K/AKT and Wnt/b-catenin signaling in IECs
suggests that these 2 pathways likely contribute to the
beneﬁcial actions of GLP-2 in the mouse TPN model.
Because of the lack of conditional GLP2R-deﬁcient mice, it
was not possible to perform the reciprocal experiment
and test if exogenous EGF required cell type–speciﬁc
GLP2R signaling to attenuate TPN-induced mucosal
atrophy.

Exogenous GLP-2 Does Not Require Functional
PI3K-pAKT Signaling in IECs for its Beneﬁcial
Actions on Mucosal Atrophy in the TPN Model
Because exogenous EGF and GLP-2 stimulated pAKT
activity in TPN-treated WT mice, we next examined if the
beneﬁcial effects of these 2 growth factors were dependent
on PI3K-pAKT signaling in IECs. For this analysis, conditional IEC-speciﬁc pi3kr1KO (termed IEC-pi3kr1KO) mice
were used in which the class IA subunit of PI3K was
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Figure 6. IEC-EgfrKO mice show no overt intestinal phenotype under normal physiological conditions. (A) PCR analysis
showing efﬁcient Egfr recombination in isolated colonic crypts from Egfrﬂox/ﬂox and IEC-EgfrKO (Villin-Cre;Egfrﬂox/ﬂoxf) mice.
(B) Real-time PCR analysis of wild-type Egfr mRNA expression in isolated colonic crypts (n ¼ 2 per genotype). Exon
3–anchored primer analysis shows that no wild-type Egfr mRNA is detected in colonic epithelium from IEC-EgfrKO mice.
(C) Western blot (WB) analysis of EGFR protein expression in isolated colonic crypts. No EGFR protein is detected in colonic
epithelium from IEC-EgfrKO mice. (D) H&E analysis of the jejunum. No overt changes in crypt–villus architecture are observed in
IEC-EgfrKO mice. Scale bars: 100 um.

conditionally deleted in IECs.31 IEC-pi3kr1KO mice have no
intestinal phenotype at baseline31 but consistent with a
loss of functional PI3K activity in IECs, pAKT (S473) levels
were reduced dramatically in IECs of IEC-pi3kr1KO mice
under all experimental conditions (Figure 8). Similar to the
previous IEC-EgfrKO studies, only a direct comparison of
IEC responses to exogenous growth factor treatments in
TPN-treated IEC-pi3kr1KO and pi3kr1ﬂ/ﬂ genotype control
mice was performed. Surprisingly, exogenous GLP-2 still
was able to attenuate mucosal atrophy in TPN-treated IECpi3kr1KO mice. In TPN-treated IEC-pi3kr1KO mice given
GLP-2, crypt depth and villus height were completely
restored whereas crypt cell proliferation vastly was
improved, although it did not reach the same levels of
genotype control mice (Figure 9A–C). Similarly, although
crypt IEC apoptosis was increased slightly, it was still
greatly diminished compared with the increased apoptosis
observed in TPN-treated IEC-pi3kr1KO mice receiving EGF
(see next section) (Figure 9D). Thus, unlike the dramatic
loss of protective IEC responses observed in TPN-treated

IEC-EgfrKO mice receiving GLP-2, exogenous GLP-2 still
had signiﬁcant beneﬁcial effects against mucosal atrophy
in the absence of intestinal PI3K-pAKT signaling.
The protective effects of GLP-2 on TPN-treated IECpi3kr1KO mice also were reﬂected in an overall improvement
in Wnt/b-catenin signaling in IECs with both total cytoplasmic b-catenin and nuclear p-b-catenin (S552) protein
levels being restored completely (Figure 9E and F).
Consistent with improved crypt cell proliferation and
restoration of Wnt/b-catenin signaling, nuclear cyclin D1
and c-Myc protein levels also were restored to genotype
control levels (Figure 9G). These data clearly show that an
intact PI3K/pAKT signaling pathway in IECs is not essential
for exogenous GLP-2 to protect against loss of crypt cell
proliferation and the increase in IEC apoptosis observed in
the TPN model. Importantly, the preservation of nuclear
b-catenin (S552) with exogenous GLP-2 in TPN-treated IECpi3kr1KO mice suggests that GLP-2 can drive IEC proliferation via an EGFR/Wnt/b-catenin pathway that is regulated
independently of intestinal PI3K/pAKT signaling. Although

Figure 5. (See previous page). Both exogenous GLP-2 and EGF regulate pAKT and Wnt/b-catenin signaling in IECs to
reduce TPN-induced mucosal atrophy. (A) Western blot analysis of pAKT (S473), p-b-catenin (S33/37/T41), and pGSK3b in
cytoplasmic extracts. Lower panels: Quantiﬁcation of each phospho-speciﬁc protein. pAKT (S473) (n ¼ 4 per group),
p-b-catenin (S33/37/T41) (n ¼ 3–5 per group), and pGSK3b (n ¼ 4–5 per group). (B) Western blot analysis of p-b-catenin (S552)
in nuclear extracts. Lower panel: Quantiﬁcation of p-b-catenin (S552) protein levels (n ¼ 4–5 per group). (C) Immunostaining of
p-b-catenin (S552)þ cells in the jejunum. Right panel: Quantiﬁcation of p-b-catenin (S552)þ cells per crypt (n ¼ 4–5 per group).
(D) Western blot analysis of cyclin D1 and c-Myc in nuclear extracts. Right panels: Quantiﬁcation of nuclear cyclin D1 and
c-Myc protein levels (n ¼ 4–5 per group). *P < .05, **P < .01, ***P < .001, and ****P < .0001. Scale bars: 50 um. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; norm, normal.
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Figure 8. TPN-treated IEC-pik3r1KO mice administered exogenous GLP-2 or EGF show a marked loss of functional
pAKT signaling in IECs. (A) Western blot analysis of pAKT (S473) and total AKT protein levels in cytoplasmic extracts
from IECs. (B) Quantiﬁcation of pAKT (S473) protein levels normalized to total AKT protein levels (n ¼ 3 per group). **P < .01,
***P < .001.

not a direct focus of the current study, it will be important
to determine whether exogenous GLP-2 can produce similar
IEC responses in the absence of PI3K/AKT signaling under
normal intestinal homeostasis and during adaptive responses to refeeding.

Protective Effect of Exogenous EGF on
TPN-Induced Mucosal Atrophy Requires
Functional PI3K-pAKT Signaling in IECs
Based on the earlier-described observations with
exogenous GLP-2, we next examined whether exogenous
EGF required functional PI3K-pAKT signaling in IECs to
attenuate TPN-induced mucosal atrophy. As expected,
exogenous EGF protected TPN-treated genotype control
mice against mucosal atrophy similar to TPN-treated WT
mice given EGF. By contrast, exogenous EGF failed to
protect against mucosal atrophy in IEC-pi3kr1KO mice
receiving TPN. Indeed, TPN-treated IEC-pi3kr1KO mice
given EGF showed signiﬁcant reductions in crypt depth,
villus height, and crypt cell proliferation, whereas IEC
apoptosis was increased dramatically compared with the
TPN-treated genotype control mice receiving EGF
(Figure 9A–D).
Importantly,
isolated
IECs
from
TPN-treated
IEC-pi3kr1KO mice given EGF showed sustained levels of
cytoplasmic p-b-catenin (S33/37/T41) whereas nuclear
p-b-catenin (S552) levels remained diminished, indicating
that EGF could not restore Wnt/b-catenin signaling in IECs
in the absence of functional PI3K-AKT signaling (Figure 9E

and F). Furthermore, exogenous EGF failed to restore
nuclear cyclin D1 and c-Myc protein levels, providing
additional evidence that exogenous EGF was unable to
restore Wnt/b-catenin signaling in IECs of TPN-treated IECpi3kr1KO mice (Figure 9G). Together, these results indicate
that the beneﬁcial effects of exogenous EGF upon TPNassociated mucosal atrophy require intestinal EGFR/PI3K/
pAKT signaling, which plays a critical role for maintaining
functional Wnt/b-catenin signaling in IECs of TPN-treated
mice.

GLP-2 and EGF Signaling Are Decreased in
Unfed Human Small Intestine
To address whether the reduction in GLP-2 and EGF
signaling associated with enteral nutrient deprivation in
the mouse also is observed in human beings, paired samples of fed and unfed distal small bowel were collected
from patients undergoing planned loop ileostomy takedowns. Although these patients were not on TPN, our
laboratory has shown that the adverse effects of TPN are
caused by enteral nutrient deprivation and not the mere
administration of parenteral nutrition solution.51 Importantly, the pairing of matched fed and unfed samples from
the same patient allowed for direct analysis of any differences in signaling independently of interindividual variation. To assess EGF and GLP-2 signaling in the human
samples, EGF, EGFR, proglucagon, and GLP2R mRNA
expression was measured in fed and unfed ileum obtained
from 8 different patients. Interestingly, a signiﬁcant

Figure 7. (See previous page). Exogenous GLP-2 does not improve mucosal atrophy in TPN-treated IEC-EgfrKO mice.
(A) Quantiﬁcation of small intestinal crypt depth and villus height (n ¼ 7–8 per group). (B) Immunoﬂuorescent staining of PCNAþ
cells in the jejunum. Right panel: Quantiﬁcation of PCNAþ cells per crypt expressed as a Proliferation Index. (C) Immunoﬂuorescent staining of TUNELþ cells in the jejunum. White arrowheads, TUNELþ cells. Right panels: Quantiﬁcation of TUNELþ
cells in crypt compartment. (D) Western blot analysis of pAKT (S473), p-b-catenin (S33/37/T41), and pGSK3b in cytoplasmic
extracts. Lower panel: Quantiﬁcation of each phospho-speciﬁc protein (n ¼ 3 per group). (E) Western blot analysis of
p-b-catenin (S552) in nuclear extracts. Lower panel: Quantiﬁcation of p-b-catenin (S552) protein levels. (F) Immunostaining of
p-b-catenin (S552)þ cells in the jejunum. Lower panel: Quantiﬁcation of p-b-catenin (S552)þþ cells per crypt. (G) Western blot
analysis of cyclin D1 and c-Myc in nuclear extracts. Right panels: Quantiﬁcation of nuclear cyclin D1 and c-Myc protein levels.
All treatment groups (n ¼ 5) unless speciﬁed differently. ***P < .001, ****P < .0001. Scale bars: 50 um. DAPI, 40 ,6-diamidino-2phenylindole; norm, normal.
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decrease in EGF, EGFR, and proglucagon mRNA expression
levels was observed in unfed segments compared with
matched fed segments. However, no difference in GLP2R
mRNA expression was detected in the unfed samples

A

B

(Figure 10A). Although insufﬁcient tissue was available to
perform immunostaining from all 8 patients, PCNAþ crypt
cells were reduced signiﬁcantly in the unfed compared
with matched-fed samples from 5 patients (Figure 10B). In
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Figure 10. Reduced GLP2 and EGF signaling is
associated
with
decreased cell proliferation
and
increased
apoptosis
in
unfed
human small intestine.
Analysis of fed and unfed
segments of ileum from
patients undergoing planned loop ileostomy takedowns. (A) Real-time PCR
analysis of EGF, EGFR,
proglucagon (GCG), and
GLP2R mRNA expression
in scraped mucosa from
fed and unfed ileal segments (n ¼ 8). (B) Immunoﬂuorescent staining of
PCNA. Quantiﬁcation of
PCNAþ cells per crypt
(n ¼ 5). (C) Real-time PCR
analysis of anti-apoptotic
markers BCL-2 and BCL
XL mRNA expression in
scraped mucosa from fed
and unfed ileal segments
(n ¼ 8). *P < .05, all other
P values are listed in
Figure.
DAPI,
40 ,6diamidino-2-phenylindole.
Scale bars: 50 um.

Figure 9. (See previous page). Exogenous GLP-2 but not EGF can protect against mucosal atrophy in TPN-treated IECpi3kr1KO mice. (A) Quantiﬁcation of small intestinal crypt depth (n ¼ 7–8 per group). (B) Quantiﬁcation of small intestinal villus
height (n ¼ 7–8 per group). (C) Immunoﬂuorescent staining of PCNAþ cells in the jejunum. Right panel: Quantiﬁcation of
PCNAþ cells per crypt expressed as a Proliferation Index. (D) Immunoﬂuorescent staining of TUNELþ cells in the jejunum.
White arrowheads, TUNELþ cells. Right panels: Quantiﬁcation of TUNELþ cells in crypt compartment. (E) Western blot
analysis of p-b-catenin (S33/37/T41) and pGSK3b in cytoplasmic extracts. Lower panels: Quantiﬁcation of each phosphospeciﬁc protein (n ¼ 3 per group). (F) Western blot analysis of p-b-catenin (S552) in nuclear extracts. Lower panel:
Quantiﬁcation of p-b-catenin (S552) protein levels. (G) Western blot analysis of cyclin D1 and c-Myc in nuclear extracts
*P < .05, **P < .01. Lower panels: Quantiﬁcation of cyclin D1 and c-Myc protein levels. All treatment groups (n ¼ 5) unless
speciﬁed differently. ***P < .001, ****P < .0001. Scale bars: 50 um. GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
DAPI, 40 ,6-diamidino-2-phenylindole. *P < .05, **P < .01
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Figure 11. Mucosal IGF-1
and
IGF-1R
mRNA
expression levels in the
mouse TPN model. IGF-1
and IGF-1R mRNA levels
were measured in scraped
mucosa from all 6 TPN
treatment groups used in
this study. (A) Real-time
PCR analysis of IGF-1
mRNA expression (n ¼
5–7 per group). (B)
Real-time PCR analysis of
IGF-1R mRNA expression
in scraped mucosa (n ¼
5–7 per group). **P < .01,
***P < .001, and ****P <
.0001.
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TPN, an essential therapy for patients who cannot
tolerate enteral nutrition, is associated with mucosal atrophy, barrier dysfunction, and increased clinical complications including higher rates of septicemia.2,3,52,53 In
addition, a signiﬁcant decrease in mucosally derived growth
factors has been reported in TPN patients and in animal
models of TPN.4,26,36,54,55 Thus, for patients dependent on
TPN, a promising strategy to improve intestinal growth and
maintain epithelial barrier function has been with the use of
exogenous growth factors.56 GLP-2 and GLP-2 analogues
have been used successfully in TPN patients to promote
intestinal adaptation, improve small intestinal surface area
and absorptive function, and can facilitate withdrawal from
parenteral nutrition.5,6,57 Similarly, EGF has been shown to
have considerable beneﬁt for pediatric patients with SBS
and necrotizing enterocolitis.58,59 GLP-2 and EGF also have
shown synergistic beneﬁcial responses in a rat model of
TPN,27 however, limited information is available on whether

TP

Discussion

the biological actions of these 2 growth factors occur
through overlapping or distinct signaling pathways in the
TPN model.56
In the present work, we explored the interactions between EGF and GLP-2 in a mouse TPN model. In WT mice
receiving TPN, we found reductions in endogenous EGF and
GLP-2 signaling pathways including decreased GLP-2
plasma levels and decreased EGF, EGFR, and GLP2R
expression in the intestine. Consistent with previous reports
in the mouse TPN model,4,25 both exogenous EGF and GLP-2
attenuated TPN-induced mucosal atrophy and, in both cases,
this was associated with maintenance of speciﬁc components from each other’s signaling pathway. Reciprocal
receptor-inhibitor studies using the EGFR kinase inhibitor
geﬁtinib and the GLP-2 antagonist GLP-2 (3-33) clearly
showed strong interdependency for the beneﬁcial effects of
each growth factor, which required activation of downstream AKT and b-catenin signaling. At a cellular level, we
investigated the requirements for EGFR and PI3K/pAKT
signaling in IECs using IEC-EgfrKO and IEC-pi3kr1KO mice. We
found that the beneﬁcial actions of both growth factors
required functional EGFR signaling in IECs. Surprisingly,
however, EGF was completely dependent on downstream
PI3K/pAKT signaling in IECs, whereas GLP-2 appears to
attenuate mucosal atrophy and improve IEC proliferation
independently of the PI3K pathway. The sustained nuclear
b-catenin signaling observed after GLP-2 treatment in
the absence of PI3K signaling suggests that activation of the
Wnt/b-catenin pathway by GLP-2 may contribute to the
attenuation of mucosal atrophy. Finally, we showed that
many of the same features of mucosal atrophy observed in
the mouse TPN model are recapitulated in the human ileum
upon nutrient deprivation. These ﬁndings indicate that
further investigations into the interdependency of EGF and
GLP-2 signaling pathways, at a cellular level, may yield new
insights into strategies to augment intestinal adaptation.

Fold Change (104)
(relative to 18S mRNA)

addition, in the 1 patient tested, TUNELþ staining of IECs
was increased in the unfed segment compared with the
matched-fed sample (data not shown). To further examine
if IEC apoptosis was increased in the unfed samples, we
measured changes in mRNA expression of the antiapoptotic factors, BCL-2 and BCL-Xl. Signiﬁcant
reductions in BCL-2 and BCL-Xl mRNA levels were observed
in the unfed segments of ileum compared with the fed
control samples from all 8 patients (Figure 10C). Thus,
similar to enteral nutrient deprivation in the mouse TPN
model, these results indicate that both EGF and GLP-2
signaling pathways are reduced and likely contribute to
the reduction in crypt cell proliferation and increased IEC
apoptosis observed upon enteral nutrient deprivation in
the human ileum.
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The intestinal stem cell niche contains various accessory cells within the lamina propria such as subepithelial
myoﬁbroblasts, enteric neurons, and myeloid cells that
provide important, but often redundant, paracrine signals
that maintain the crypt stem cell/progenitor compartment.
Previous studies have highlighted the importance of ErbB
ligand production and EGFR signaling from subepithelial
myoﬁbroblasts and myeloid cells for IEC responses during
intestinal inﬂammation and tumorigenesis.60,61 Although
exogenous GLP-2 maintained mucosal EGF expression in
the present study, we previously reported that many other
ErbB ligands are down-regulated in the mouse TPN model.

Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 3

For example, down-regulation of neuregulin-4, which speciﬁcally binds to ErbB4 receptors, is directly dependent on
enhanced TNFa signaling associated with the mild proinﬂammatory state observed in the mouse TPN model.19,21
Interestingly, exogenous GLP-2 can acutely induce expression of other ErbB ligands that are required for IEC proliferation in WT mice and after refeeding.15,16 Likewise,
exogenous EGF restored mucosal Nrg4 mRNA expression in
TPN-treated mice.19 These results indicate that paracrine
signaling through other ErbB receptors likely contributes
to the beneﬁcial actions of exogenous GLP-2 and EGF in
the TPN model. Indeed, in preliminary studies using

May 2017

IEC-speciﬁc ErbB4KO mice we have observed exacerbated
TPN-associated mucosal atrophy.62 Further studies will be
needed to address which accessory cells produce these
different ErbB ligands, how their expression is regulated,
and whether they act primarily as paracrine growth
factors.
In addition to ErbB ligands, other paracrine factors have
been implicated in the beneﬁcial actions of GLP-2 in the
intestine, including IGF-1. Analysis of IEC-IGF-1RKO mice
showed that IGF-1R and downstream activation of b-catenin
signaling in IECs is required for GLP-2 effects on acute IEC
proliferation and intestinal adaptation responses.12,14
Considering that IGF-1R and EGFR/ErbB families show
homology in their structure and both the receptors share
considerable cross-talk in their functions,63 it is not surprising that several GLP-2 studies have reported interactions between these 2 growth factor systems in the
intestine. Rowland et al14 reported reduced mucosal Heparin-binding EGF-like growth factor (HB-EGF) and EGFR
mRNA levels in IEC-IGF-1RKO mice. On the other hand,
mucosal EGF and IGF-1R mRNA levels were signiﬁcantly
lower in Glp2r-deﬁcient mice under basal conditions,
whereas EGFR, ErbB ligand epiregulin, and IGF-1 mRNA
expression was reduced in refed Glp2r-deﬁcient mice
compared with refed WT mice.15,16 In our own preliminary
studies, IGF-1 and IGF-1R mRNA expression levels were
unchanged after 6-day TPN administration and were not
altered by exogenous GLP-2 treatment. However, exogenous
EGF markedly increased IGF-1R mRNA levels independently
of GLP2R signaling whereas IGF-1 mRNA levels remained
unchanged (Figure 11). Taken together, these ﬁndings show
complex interactions between GLP2R signaling and paracrine growth factors that activate EGFR and IGF-1R
signaling pathways in IECs. Intriguingly, the ability of
exogenous GLP-2 to protect against TPN-associated mucosal
atrophy independently of intestinal PI3K but still requiring
Wnt/b-catenin signaling raises the possibility that intact
IGF-1/IGF-1R signaling observed in the mouse TPN model
may be involved in this process (Figure 12). Indeed,
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accumulating evidence suggests that IGF-1/IGF-1R signaling
can activate b-catenin through several different mechanisms including IRS-1–dependent pathways.64,65 Although
beyond the scope of the present work, it will be important
to examine the requirement of IGF-1R signaling in IECs for
this response and to directly compare GLP-2 actions in both
IEC-EgfrKO and IEC-Igf-1rKO mice in the mouse TPN model.
Because of continuous cell turnover and high rates of
proliferation, the intestinal stem cell (ISC)/progenitor cell
populations of the crypt compartment are very metabolically active. Loss of enteral nutrition through long-term
caloric depletion, fasting, or parenteral nutrition can alter
the function of ISC/progenitor populations as well as that of
other accessory cells in the intestinal stem cell niche such as
Paneth cells.66–68 Previous studies have shown that phosphatase and tensin homolog, a negative regulator of the
PI3K/AKT/mammalian target of rapamycin complex 1
(mTORC1)-signaling pathway, is an important regulator of
reserve facultative ISCs.67 Upon fasting, the number of
rapidly recycling leucine-rich repeat-containing G-protein–coupled receptor 5 (Lgr5)þ cells is reduced, but at the
same time phosphatase and tensin homolog is selectively
inhibited in reserve ISCs making them competent during
refeeding to be mobilized and replenish the Lgr5þ stem cell
pool; a process that is dependent on PI3K/AKT/mTORC1
activation. By contrast, under conditions of long-term
caloric restriction, Lgr5þ ISC self-renewal is regulated
indirectly by decreased mTORC1 signaling in neighboring
Paneth cells.68 In the mouse TPN model, we recently
showed that both Lgr5þ ISCs and Paneth cell populations
are diminished after 6 days of TPN administration. Although
the loss of Lgr5þ ISCs is consistent with a marked reduction
in AKT phosphorylation observed in whole IEC isolates
analyzed in this study, it will be important to conﬁrm these
ﬁndings directly within the crypt stem cell compartment.
Because activation of PI3K/pAKT signaling in IECs is
essential for the beneﬁcial effects of EGF treatment but not
GLP-2 in the TPN model, it raises the possibility that other
signaling pathways besides IGF-1/IGF-1R may contribute to

Figure 12. (See previous page). Summary of the interdependency of EGF and GLP-2 signaling to attenuate mucosal
atrophy in a mouse TPN model. Exogenous EGF and GLP-2 treatment attenuate TPN-associated mucosal atrophy. Based
on the results from reciprocal receptor inhibition studies and analyses of IEC responses in IEC-EgfrKO and IEC-pi3kr1KO mice,
the requirements of EGFR- and PI3K/pAKT-dependent pathways in IECs for the beneﬁcial actions of these 2 growth factors
are summarized. Top panel: TPN alone. TPN alone reduces components of endogenous EGF and GLP-2 signaling in the
intestinal mucosa. Importantly, TPN leads to a reduction in functional EGFR signaling in IECs, decreased cytoplasmic PI3k/
pAKT signaling, and decreased p-b-catenin (S552), c-Myc, and cyclin D1 levels leading to mucosal atrophy. Middle panel: TPN
plus exogenous EGF. Exogenous EGF treatment restores GLP-2 plasma levels, mucosal GLP2R expression, and EGFR
protein levels in IECs. Exogenous EGF also may enhance the production of ErbB ligands from other lamina propria cells that
activate other ErbB receptors on IECs (not shown). The beneﬁcial actions of exogenous EGF are dependent on functional
EGFR and PI3K/pAKT signaling in IECs. EGFR/PI3K/pAKT signaling is required for maintenance of nuclear p-B-catenin (S552),
c-Myc, and cyclin D1 levels needed to improve IEC responses and attenuate mucosal atrophy. Bottom panel: TPN plus
exogenous GLP-2. Exogenous GLP-2 treatment robustly increases GLP-2 plasma levels and restores mucosal EGF
expression. Exogenous GLP-2 also may increase expression of other ErbB ligands in GLP2R-expressing lamina propria cells
that activate other ErbB receptors on IECs (not shown). The beneﬁcial actions of exogenous GLP-2 are dependent on
functional EGFR signaling in IECs, but GLP-2 still can attenuate mucosal atrophy in the absence of PI3K/pAKT signaling in
IECs. Importantly, functional EGFR signaling but not PI3k/pAKT signaling in IECs is required for maintenance of nuclear
p-B-catenin (S552), c-Myc, and cyclin D1 levels needed to improve IEC responses and attenuate mucosal atrophy. As noted,
complex cross-talk between GLP2R and EGFR/ErbB signaling with other signaling pathways such as IGF-1/IGF-1R likely
contributes to these beneﬁcial IEC responses. In IECs, IGF-1R signaling also may contribute to activation of Wnt/b-catenin
signaling independently of the PI3K/pAKT pathway (see Discussion section for more details).
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the actions of GLP-2 in regulating the stem cell niche during
enteral nutrient deprivation. Recent ablation studies have
shown that Foxl1þ subepithelial mesenchymal cells provide
essential paracrine signals including Wnt ligands for the
maintenance of the intestinal stem cell niche.69 An alternative possibility is that GLP-2 may stimulate Wnt ligand/
R-spondin production from accessory cells of the stem cell
niche, thereby enhancing Wnt/b-catenin signaling within
the crypt compartment. Future work will be needed to test
this hypothesis and to further dissect out the contribution of
canonical vs noncanonical Wnt pathways for the actions of
GLP-2 actions in the mouse TPN model. Consistent with a
loss of IEC proliferation observed in healthy volunteers
maintained on TPN,53 we showed a reduction of EGF and
GLP-2 signaling components, reduced IEC proliferation, and
increased IEC apoptosis in human small bowel not exposed
to enteral nutrition, suggesting that a similar effect occurs
on a clinical basis. It will be important to determine how
these distinct downstream signaling pathways regulate
different ISC/progenitor populations after TPN administration and whether the same pathways are required for
regulation of the intestinal stem cell niche from patients
dependent on TPN.
In summary, we have shown a striking co-dependency of
EGF and GLP-2 and their downstream signal transduction
pathways in attenuating mucosal atrophy in the mouse
model of TPN (summarized in Figure 12). These ﬁndings
suggest that newer strategies that preserve both of these
signals will lead to the most optimal clinical treatment of
disorders such as short-bowel syndrome.

References
1. Minard G, Kudsk KA. Nutritional support and infection:
does the route matter? World J Surg 1998;22:213–219.
2. Moore FA, Moore EE, Jones TN, et al. TEN versus TPN
following major abdominal trauma–reduced septic
morbidity. J Trauma 1989;29:916–923.
3. Casaer MP, Mesotten D, Hermans G, et al. Early versus
late parenteral nutrition in critically ill adults. N Engl J
Med 2011;365:506–517.
4. Demehri FR, Barrett M, Ralls MW, et al. Intestinal
epithelial cell apoptosis and loss of barrier function in the
setting of altered microbiota with enteral nutrient deprivation. Front Cell Infect Microbiol 2013;3:105.
5. Sigalet DL, Brindle M, Boctor D, et al. A safety and
dosing study of glucagon-like peptide 2 in children with
intestinal failure. JPEN J Parenter Enteral Nutr 2017
Jan 29, pii: S0022-3468(17)30067-2.
6. Schwartz LK, O’Keefe SJ, Fujioka K, et al. Long-term
teduglutide for the treatment of patients with intestinal
failure associated with short bowel syndrome. Clin Transl
Gastroenterol 2016;7:e142.
7. Brubaker PL, Izzo A, Hill M, et al. Intestinal function in
mice with small bowel growth induced by glucagon-like
peptide-2. Am J Physiol 1997;272:E1050–E1058.
8. Drucker DJ, Yusta B. Physiology and pharmacology of
the enteroendocrine hormone glucagon-like peptide-2.
Annu Rev Physiol 2014;76:561–583.

Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 3
9. Rowland KJ, Brubaker PL. The “cryptic” mechanism of
action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol 2011;301:G1–G8.
10. Orskov C, Hartmann B, Poulsen SS, et al. GLP-2 stimulates colonic growth via KGF, released by subepithelial
myoﬁbroblasts with GLP-2 receptors. Regul Pept 2005;
124:105–112.
11. Dube PE, Forse CL, Bahrami J, et al. The essential role of
insulin-like growth factor-1 in the intestinal tropic effects
of glucagon-like peptide-2 in mice. Gastroenterology
2006;131:589–605.
12. Dube PE, Rowland KJ, Brubaker PL. Glucagon-like
peptide-2 activates beta-catenin signaling in the mouse
intestinal crypt: role of insulin-like growth factor-I.
Endocrinology 2008;149:291–301.
13. Leen JL, Izzo A, Upadhyay C, et al. Mechanism of action
of glucagon-like peptide-2 to increase IGF-I mRNA in
intestinal subepithelial ﬁbroblasts. Endocrinology 2011;
152:436–446.
14. Rowland KJ, Trivedi S, Lee D, et al. Loss of glucagon-like
peptide-2-induced proliferation following intestinal
epithelial insulin-like growth factor-1-receptor deletion.
Gastroenterology 2011;141:2166–2175 e7.
15. Yusta B, Holland D, Koehler JA, et al. ErbB signaling is
required for the proliferative actions of GLP-2 in the
murine gut. Gastroenterology 2009;137:986–996.
16. Bahrami J, Yusta B, Drucker DJ. ErbB activity links the
glucagon-like peptide-2 receptor to refeeding-induced
adaptation in the murine small bowel. Gastroenterology
2010;138:2447–2456.
17. Hare KJ, Hartmann B, Kissow H, et al. The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in
mice induced by the epidermal growth factor receptor
inhibitor, geﬁtinib. Clin Cancer Res 2007;13:5170–5175.
18. Feng Y, McDunn JE, Teitelbaum DH. Decreased
phospho-Akt signaling in a mouse model of total
parenteral nutrition: a potential mechanism for the
development of intestinal mucosal atrophy. Am J Physiol
Gastrointest Liver Physiol 2010;298:G833–G841.
19. Feng Y, Teitelbaum DH. Epidermal growth factor/TNFalpha transactivation modulates epithelial cell proliferation and apoptosis in a mouse model of parenteral
nutrition. Am J Physiol Gastrointest Liver Physiol 2012;
302:G236–G249.
20. Feng Y, Teitelbaum DH. Tumour necrosis factor–induced
loss of intestinal barrier function requires TNFR1 and
TNFR2 signalling in a mouse model of total parenteral
nutrition. J Physiol 2013;591:3709–3723.
21. Feng Y, Tsai YH, Xiao W, et al. Loss of ADAM17mediated tumor necrosis factor alpha signaling in intestinal cells attenuates mucosal atrophy in a mouse model
of parenteral nutrition. Mol Cell Biol 2015;35:3604–3621.
22. Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2
dose-dependently activates intestinal cell survival and
proliferation in neonatal piglets. Endocrinology 2005;
146:22–32.
23. Burrin DG, Stoll B, Jiang R, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest
Liver Physiol 2000;279:G1249–G1256.

May 2017
24. Chance WT, Foley-Nelson T, Thomas I, et al. Prevention
of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 1997;
273:G559–G563.
25. Lei Q, Bi J, Wang X, et al. GLP-2 prevents intestinal
mucosal atrophy and improves tissue antioxidant capacity in a mouse model of total parenteral nutrition.
Nutrients 2016;8:33.
26. Sangild PT, Tappenden KA, Malo C, et al. Glucagon-like
peptide 2 stimulates intestinal nutrient absorption in
parenterally fed newborn pigs. J Pediatr Gastroenterol
Nutr 2006;43:160–167.
27. Kitchen PA, Goodlad RA, FitzGerald AJ, et al. Intestinal
growth in parenterally-fed rats induced by the combined
effects of glucagon-like peptide 2 and epidermal growth
factor. JPEN J Parenter Enteral Nutr 2005;29:248–254.
28. Suri M, Turner JM, Sigalet DL, et al. Exogenous
glucagon-like peptide-2 improves outcomes of intestinal
adaptation in a distal-intestinal resection neonatal piglet
model of short bowel syndrome. Pediatr Res 2014;
76:370–377.
29. el Marjou F, Janssen KP, Chang BH, et al. Tissue-speciﬁc and inducible Cre-mediated recombination in the
gut epithelium. Genesis 2004;39:186–193.
30. Ireland H, Kemp R, Houghton C, et al. Inducible Cremediated control of gene expression in the murine
gastrointestinal tract: effect of loss of beta-catenin.
Gastroenterology 2004;126:1236–1246.
31. Lee G, Goretsky T, Managlia E, et al. Phosphoinositide
3-kinase signaling mediates beta-catenin activation in
intestinal epithelial stem and progenitor cells in colitis.
Gastroenterology 2010;139:869–881, e1–9.
32. Lee TC, Threadgill DW. Generation and validation of mice
carrying a conditional allele of the epidermal growth
factor receptor. Genesis 2009;47:85–92.
33. Luo J, McMullen JR, Sobkiw CL, et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 2005;
25:9491–9502.
34. Thulesen J, Knudsen LB, Hartmann B, et al. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2
receptor as a partial agonist. Regul Pept 2002;103:9–15.
35. Karaman MW, Herrgard S, Treiber DK, et al.
A quantitative analysis of kinase inhibitor selectivity. Nat
Biotechnol 2008;26:127–132.
36. Brinkman AS, Murali SG, Hitt S, et al. Enteral nutrients
potentiate glucagon-like peptide-2 action and reduce
dependence on parenteral nutrition in a rat model of
human intestinal failure. Am J Physiol Gastrointest Liver
Physiol 2012;303:G610–G622.
37. Brubaker PL, Crivici A, Izzo A, et al. Circulating and tissue
forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997;138:4837–4843.
38. Grossmann J, Maxson JM, Whitacre CM, et al. New
isolation technique to study apoptosis in human intestinal epithelial cells. Am J Pathol 1998;153:53–62.
39. Dekaney CM, Rodriguez JM, Graul MC, et al. Isolation
and characterization of a putative intestinal stem cell
fraction from mouse jejunum. Gastroenterology 2005;
129:1567–1580.

EGF and GLP-2 Cell Growth

467

40. Traber PG, Gumucio DL, Wang W. Isolation of intestinal
epithelial cells for the study of differential gene expression along the crypt-villus axis. Am J Physiol 1991;
260:G895–G903.
41. John LJ, Fromm M, Schulzke JD. Epithelial barriers in
intestinal inﬂammation. Antioxid Redox Signal 2011;
15:1255–1270.
42. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inﬂammatory bowel diseases. Inﬂamm
Bowel Dis 2011;17:362–381.
43. Shin ED, Estall JL, Izzo A, et al. Mucosal adaptation to
enteral nutrients is dependent on the physiologic actions
of glucagon-like peptide-2 in mice. Gastroenterology
2005;128:1340–1353.
44. Garrison AP, Dekaney CM, von Allmen DC, et al. Early
but not late administration of glucagon-like peptide-2
following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver
Physiol 2009;296:G643–G650.
45. Okawada M, Holst JJ, Teitelbaum DH. Administration of
a dipeptidyl peptidase IV inhibitor enhances the intestinal
adaptation in a mouse model of short bowel syndrome.
Surgery 2011;150:217–223.
46. Trivedi S, Wiber SC, El-Zimaity HM, et al. Glucagon-like
peptide-2 increases dysplasia in rodent models of colon
cancer. Am J Physiol Gastrointest Liver Physiol 2012;
302:G840–G849.
47. Yusta B, Estall J, Drucker DJ. Glucagon-like peptide-2
receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner
and prevents apoptosis following inhibition of phosphatidylinositol
3-kinase.
J
Biol
Chem
2002;
277:24896–24906.
48. Munroe DG, Gupta AK, Kooshesh F, et al. Prototypic G
protein-coupled receptor for the intestinotrophic factor
glucagon-like peptide 2. Proc Natl Acad Sci U S A 1999;
96:1569–1573.
49. Lim DW, Wales PW, Turner JM, et al. On the horizon:
trophic peptide growth factors as therapy for neonatal
short bowel syndrome. Expert Opin Ther Targets 2016;
20:819–830.
50. Yan F, Cao H, Cover TL, et al. Colon-speciﬁc delivery of a
probiotic-derived soluble protein ameliorates intestinal
inﬂammation in mice through an EGFR-dependent
mechanism. J Clin Invest 2011;121:2242–2253.
51. Wildhaber BE, Yang H, Spencer AU, et al. Lack of enteral
nutrition–effects on the intestinal immune system. J Surg
Res 2005;123:8–16.
52. Buzby GP. Overview of randomized clinical trials of total
parenteral nutrition for malnourished surgical patients.
World J Surg 1993;17:173–177.
53. Buchman AL, Moukarzel AA, Bhuta S, et al. Parenteral
nutrition is associated with intestinal morphologic and
functional changes in humans. JPEN J Parenter Enteral
Nutr 1995;19:453–460.
54. Hua Z, Turner JM, Sigalet DL, et al. Role of glucagon-like
peptide-2 deﬁciency in neonatal short-bowel syndrome
using neonatal piglets. Pediatr Res 2013;73:742–749.
55. McAndrew HF, Lloyd DA, Rintala R, et al. The effects of
intravenous epidermal growth factor on bacterial

468

56.

57.

58.

59.

60.

61.

62.

63.

64.

Feng et al
translocation and central venous catheter infection in the
rat total parenteral nutrition model. Pediatr Surg Int 2000;
16:169–173.
Warner BW. The pathogenesis of resection-associated
intestinal adaptation. Cell Mol Gastroenterol Hepatol
2016;2:429–438.
Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised
placebo-controlled trial of teduglutide in reducing
parenteral nutrition and/or intravenous ﬂuid requirements
in patients with short bowel syndrome. Gut 2011;
60:902–914.
Sigalet DL, Martin GR, Butzner JD, et al. A pilot study of
the use of epidermal growth factor in pediatric short
bowel syndrome. J Pediatr Surg 2005;40:763–768.
Sullivan PB, Lewindon PJ, Cheng C, et al. Intestinal
mucosa remodeling by recombinant human epidermal
growth factor(1-48) in neonates with severe necrotizing
enterocolitis. J Pediatr Surg 2007;42:462–469.
Lu N, Wang L, Cao H, et al. Activation of the epidermal
growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol
2014;192:1013–1023.
Neufert C, Becker C, Tureci O, et al. Tumor ﬁbroblastderived epiregulin promotes growth of colitisassociated neoplasms through ERK. J Clin Invest 2013;
123:1428–1443.
Feng Y, Dempsey PJ, Frey MR, et al. Intestine-speciﬁc
ErbB4 deﬁciency exacerbates TPN associated intestinal
atrophy. Gastroenterology 2014;146, S-301.
Adams TE, McKern NM, Ward CW. Signalling by the type
1 insulin-like growth factor receptor: interplay with the
epidermal growth factor receptor. Growth Factors 2004;
22:89–95.
Bortvedt SF, Lund PK. Insulin-like growth factor 1:
common mediator of multiple enterotrophic hormones
and growth factors. Curr Opin Gastroenterol 2012;
28:89–98.

Cellular and Molecular Gastroenterology and Hepatology Vol. 3, No. 3
65. Zeller E, Hammer K, Kirschnick M, et al. Mechanisms of
RAS/beta-catenin interactions. Arch Toxicol 2013;
87:611–632.
66. Feng Y, Barrett M, Hou Y, et al. Homeostasis alteration
within small intestinal mucosa after acute enteral
refeeding in total parenteral nutrition mouse model. Am J
Physiol Gastrointest Liver Physiol 2016;310:G273–G284.
67. Richmond CA, Shah MS, Deary LT, et al. Dormant
intestinal stem cells are regulated by PTEN and nutritional status. Cell Rep 2015;13:2403–2411.
68. Yilmaz OH, Katajisto P, Lamming DW, et al. mTORC1 in
the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012;486:490–495.
69. Aoki R, Shoshkes-Carmel M, Gao N, et al. Foxl1-expressing mesenchymal cells constitute the intestinal stem cell
niche. Cell Mol Gastroenterol Hepatol 2016;2:175–188.

Received September 2, 2016. Accepted December 31, 2016.
Correspondence
Address correspondence to: Peter J. Dempsey, PhD, Division of
Gastroenterology, Hepatology and Nutrition, Department of Pediatrics,
University of Colorado Medical School, Aurora, Colorado 80045. e-mail:
peter.dempsey@ucdenver.edu; fax: (303) 724–6538.
Acknowledgments
Yongjia Feng, Peter J. Dempsey, and Daniel H. Teitelbaum conceived the
study, designed the experiments, supervised the study, and drafted the
manuscript; Yongjia Feng, Farok R. Demehri, Weidong Xiao, Yu-Hwai Tsai,
Jennifer C. Jones, Constance D. Brindley, Jens J. Holst, Bolette Hartmann,
and Peter J. Dempsey acquired, analyzed, and interpreted the data; David
W. Threadgill and Terrence A. Barrett provided material support; Yongjia
Feng, Jens J. Holst, Terrence A. Barrett, and Peter J. Dempsey critically
revised the manuscript; and Daniel H. Teitelbaum and Peter J. Dempsey
provided funding.
Conﬂicts of interest
The authors disclose no conﬂicts.
Funding
This study was supported by National Institutes of Health grants
R01-DK093697 (P.J.D.), R01-AI044076 (D.H.T.), and 2RO1 DK095662
(T.A.B.).

